Meijvis S C A, Grutters J C, Thijsen S F, Rijkers G T, Biesma D H, Endeman H
Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, the Netherlands.
Neth J Med. 2011 Jan;69(1):21-6.
Community-acquired pneumonia (CAP) is a common and serious disease with significant mortality, morbidity and associated healthcare costs. Severity of pneumonia is related to the extent of the inflammatory response. Primary goal in the treatment of pneumonia is starting adequate antibiotic therapy as soon as possible. However, antimicrobial resistance among the most common bacteria causing pneumonia is increasing. For those two reasons, extended inflammatory response and increasing antibiotic resistance, it is interesting to look at adjunctive non-antibiotic therapeutic strategies aimed at modulation of the inflammatory response or at the micro-organism itself. In this review, we discuss the current knowledge regarding these therapies and their possible role in the future.
社区获得性肺炎(CAP)是一种常见且严重的疾病,具有显著的死亡率、发病率及相关医疗费用。肺炎的严重程度与炎症反应的程度相关。肺炎治疗的首要目标是尽快开始充分的抗生素治疗。然而,引起肺炎的最常见细菌的抗菌耐药性正在增加。由于这两个原因,即炎症反应的延长和抗生素耐药性的增加,研究旨在调节炎症反应或针对微生物本身的辅助性非抗生素治疗策略很有意义。在本综述中,我们讨论了关于这些疗法的现有知识及其未来可能发挥的作用。